Comparative Pharmacology
Head-to-head clinical analysis: VIORELE versus ZOVIA 1 35E 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIORELE versus ZOVIA 1 35E 28.
VIORELE vs ZOVIA 1/35E-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
VIORELE is a monoclonal antibody that binds to and inhibits the activity of interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the pathogenesis of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
ZOVIA 1/35E-28 is a combined oral contraceptive (COC) containing ethinyl estradiol and norethindrone. It inhibits ovulation via suppression of gonadotropins (FSH and LH), increases cervical mucus viscosity, and alters endometrial receptivity.
50 mg orally once daily
One tablet orally once daily at the same time each day for 21 days, followed by 7 days of placebo (inactive tablets), then repeat.
None Documented
None Documented
Terminal elimination half-life of 12–15 hours (mean 13.5 h) in healthy adults; may be prolonged in renal impairment (up to 30 h).
Ethinyl estradiol: ~17 hours (range 13-27 hours); Norethindrone: ~8 hours (range 5-14 hours). Clinical context: Steady state achieved in ~5-7 days; contraceptive effect requires consistent dosing.
Primarily renal (unchanged drug and metabolites, ~60%) and fecal (~30%), with minor biliary contribution (~10%).
Renal: ~40% as metabolites; biliary/fecal: ~40% as metabolites; unchanged drug minimal (<1%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive